Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 2.07
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Euroapi SA develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. The company was incorporated in 2021 and is based in Paris, France.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is 'cheap' on EV/EBITDA.
Data is available to registered users only
Target Price
The average target price of EAPI.PA is 3.0 and suggests 46% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Data is available to registered users only
Buy
Sell